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ABSTRACT
Epstein–Barr virus (EBV) expresses two transcrip-
tion factors, Rta and Zta, during the immediate-early
stage of the lytic cycle. The two proteins often col-
laborate to activate the transcription of EBV lytic
genes synergistically. This study demonstrates
that Rta and Zta form a complex via an intermediary
protein, MCAF1, on Zta response element (ZRE)
in vitro. The interaction among these three proteins
in P3HR1 cells is also verified via coimmunopre-
cipitation, CHIP analysis and confocal microscopy.
The interaction between Rta and Zta in vitro
depends on the region between amino acid 562
and 816 in MCAF1. In addition, overexpressing
MCAF1 enhances and introducing MCAF1 siRNA
into the cells markedly reduces the level of the syn-
ergistic activation in 293T cells. Moreover, the fact
that the synergistic activation depends on ZRE but
not on Rta response element (RRE) originates from
the fact that Rta and Zta are capable of activating
the BMRF1 promoter synergistically after an RRE
but not ZREs in the promoter are mutated. The
binding of Rta–MCAF1–Zta complex to ZRE but not
RRE also explains why Rta and Zta do not use RRE
to activate transcription synergistically. Importantly,
this study elucidates the mechanism underlying
synergistic activation, which is important to the
lytic development of EBV.
INTRODUCTION
Epstein–Barr virus (EBV) expresses two transcription
factors, Rta and Zta, during the immediate-early stage
of the lytic cycle, to activate the transcription of EBV
lytic genes (1–5). As is well known, Zta, encoded by
BZLF1, activates transcription by binding to Zta
response elements (ZRE) in promoters. Since the tran-
scription of many EBV lytic genes depends on Zta, EBV
cannot complete its lytic cycle after BZLF1 is mutated
(6,7). Meanwhile, Rta commonly binds to a deﬁned
sequence, Rta response elements (RRE), in EBV lytic pro-
moters to activate transcription (2,5,8–11). However, Rta
may activate transcription through a mechanism that is
independent of RRE binding. For example, Rta interacts
with Sp1 via an intermediary protein, MCAF1, to form a
complex on Sp1-binding sites to autoregulate the tran-
scription of its own gene, BRLF1 (12,13). Furthermore,
the transcription of several EBV late genes depends on
Rta but not on Zta (6,14–16), explaining why a
mutation in BRLF1 is devastating to viral lytic develop-
ment (6,7).
Earlier studies have established that Rta and Zta often
collaborate with each other to activate transcription syn-
ergistically of many EBV lytic genes, including BHLF1,
BMRF1 and BRLF1 (3,5,9,17–19). Although various
studies of the mechanism that underlies synergistic activa-
tion have been conducted, exactly how Rta and Zta syn-
ergistically activate transcription remains unknown. Since
earlier studies have failed to demonstrate an interaction
between Rta and Zta (5), Rta and Zta are assumed to bind
to their respective binding sites in a promoter to promote
synergistic activation. In fact, Quinlivan et al. (5) posited
that synergistic activation depends on the presence of at
least one RRE and one ZRE in a promoter. However, the
fact that Zta and Rta synergistically activate the BRLF1
promoter (18), which does not contain an RRE, is
evidence against the hypothesis that synergistic activation
depends on an RRE. In fact, Ragoczy et al. (20) suggested
that the synergistic activation of the BRLF1 promoter by
Rta and Zta depends on the binding of an unknown
protein to the promoter. Giot et al. (4) also asserted that
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with Zta via an intermediary protein to activate transcrip-
tion synergistically.
As is well known, MCAF1 promotes SETDB1/
ESET-mediated histone H3 methylation, thus facilitating
the formation of heterochromatin domains (21,22).
MCAF1 also interacts with MBD1 and Sp1 (23). When
interacting with MBD1, MCAF1 promotes MBD1-
dependent transcriptional repression (23). When interact-
ing with Sp1, MCAF1 becomes a coactivator that
enhances Sp1-mediated transcription (12,23,24). An
earlier study has demonstrated that Rta interacts with
Sp1 through MCAF1 to promote the autoregulation of
BRLF1 transcription (12). This study demonstrates that
MCAF1 interacts simultaneously with Rta and Zta. This
interaction promotes the synergistic activation of the tran-
scription of the EBV lytic genes.
MATERIALS AND METHODS
Cell lines and EBV lytic induction
P3HR1, EBV-negative Akata and BJAB cells were
cultured in RPMI 1640 medium that contained 10%
fetal calf serum. 293T cells were cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) that contained 10%
fetal calf serum. P3HR1 cells were treated with 3ng/ml of
TPA and 3mM sodium butyrate to activate the EBV lytic
cycle (25).
Plasmids
Plasmids pCMV-3, pCMV-R, pCMV-Z, pSp1-luc,
pcDNA-MCAF1, pRRE, pEGFP-Rta, pEGFP-
MCAF1-N, pET-Rta and pGEX-Rta have been described
elsewhere (12,25). Plasmids pEGFP-MCAF1-DM1,
pEGFP-MCAF1-M and pEGFP-MCAF1-DM2 were
constructed by inserting polymerase chain reaction
(PCR)-ampliﬁed DNA fragments that encoded the
MCAF1 regions from amino acid 562 to 817, 818 to
1153 and 1154 to 1270, respectively, into the ScaI–XhoI
sites in pEGFP-C1 (Clontech). Plasmids pEGFP-ZN,
pEGFP-ZM and pEGFP-ZC, which expressed truncated
Zta, were constructed by inserting PCR-ampliﬁed frag-
ments that encoded the amino acid regions from 1 to 86,
87 to 166 and 167 to 245, respectively, into the EcoRI–SalI
sites in pEGFP-C1. Plasmids pET-Zta and pGEX-Zta
were constructed by inserting full-length BZLF1 (n.t.
103155–102211 in the EBV genome) (GenBank accession
number V01555), which was ampliﬁed by PCR, into the
EcoRI–SalI sites in pET-28a (Novagen) and pGEX-4T1
(Amersham Pharmacia Biotech), respectively. A DNA
fragment that encoded the region from amino acid 562
to 884 in MCAF1 was inserted into the HindIII–XhoI
sites in pGEX-4T1 and pET-32a to yield pGEX-MCAF-
C1 and pET-MCAF1-C1, respectively. Plasmid pGEX-
MCAF1-C2 was constructed by inserting a PCR-ampliﬁed
fragment that encoded the region from amino acid 885 to
1270 in MCAF1 into the HindIII–XhoI sites in pGEX-
4T1. The synergistic activation by Rta and Zta was
studied using reporter plasmids pEAD, pBMRF1,
pBMRF1-mRRE, pBMRF1-mZRE, pBHLF1, pRRE
and pZRE (Table 1). Plasmid pEAD was constructed by
inserting a PCR-ampliﬁed DNA fragment that contained
the  332 to+20 region in BMRF1 (n.t. 79537 to 79889 on
the EBV genome) into the HindIII–XhoI sites in pGL2-
Basic (Promega). A reporter plasmid, pBMRF1, was con-
structed by inserting a PCR-ampliﬁed DNA fragment that
contained the  172 to+20 region in BMRF1 (n.t. 79698
to 79889 on the EBV genome) into the HindIII–XhoI
sites in pGL2-Basic. Plasmid pBMRF1-mRRE contains
the same sequences as pBMRF1, but with the RRE
sequence mutated from 50-ACACCACCCCCCA
AGGAC to 50-GATATCCCCCCCAAGGAC. Plasmid
pBMRF1-mZRE has the same sequence as is present in
pBMRF1, but the three ZREs in the promoter, from
upstream to downstream, were mutated from 50-TTGCT
CA, 50-TGAGCAA, and 50-TGAGTCA to 50-GGATCCA,
50-TGGATCC and 50-CAGCTGA, respectively. Another
reporter plasmid, pBHLF1, which includes four copies of
ZREs (n.t. 52769 to 52931 on the EBV genome) was con-
structed by inserting a PCR-ampliﬁed fragment into the
HindIII and XhoI sites in pGL2-Basic. Plasmid pZRE was
constructed by inserting a double-stranded oligonucleo-
tide 50-AAAGGCCGGCTGACATGGATTACTGGTCT
TTTATGAGCCATT, which had the sequence from the
 39 to+4 region in the BRLF1 promoter, into the SmaI
site in pGL2-Basic. Plasmid pCMV-Sp1 was obtained
from Guntram Suske (26). Plasmid pTag2-Zta was con-
structed by inserting a PCR-ampliﬁed DNA fragment
that encodes BZLF1 (n.t. 103155 to 102211 on the
EBV genome) to the EcoRI and XhoI sites of pCMV-
Tag2A (Stratagene). Moreover, plasmid pCMV-
R(K213A) encoded a mutant Rta that contained a
K213A mutation (12).
DNA-aﬃnity precipitation assay
A5 0-biotin end-labeled double-stranded DNA probe, Rp-
SZ, which contained the sequence from  64 to  28 in the
BRLF1 promoter (50-ATATTGCGATTGTCCCGCCCA
TGCCAATGGCTCATAA), was synthesized by Mission
Biotech, Inc. (Taipei, Taiwan). This sequence includes an
Sp1-binding site (50-CCGCCC) and a ZRE (50-TGGCTC
A). Probes Rp-mS and Rp-mZ included the same
sequence as Rp-SZ except that the Sp1 site and ZRE
were mutated to 50-ATTAAT and 50-GACTGCA, respect-
ively. In probe Rp-mSZ, both the Sp1 site and the ZRE
were mutated. Probe MRp-RZ contained the sequence
between the region  174 and  36 in the BMRF1
promoter and, then, was ampliﬁed by PCR using
biotinylated primers. In this probe, the RRE was
mutated from 50-ACACCACCCCCCAAGGAC to 50-G
ATATCCCCCCCAAGGAC to generate a probe, MRp-
mR; the three ZREs, 50-TTGCTCA, 50-TGAGCAA and
50-TGAGTCA to 50-GGATCCA, 50-TGGATCC and 50-C
AGCTGA, respectively, to generate MRp-mZ. In the
probe MRp-mRZ, RRE and ZREs were all mutated.
Probe HLp-Z (50-GTCTCTGTGTAATACTTTAAGGT
TTGCTCAGGAG) contained two ZREs, 50-TGTGTAA
and 50-TTGCTCA, from the BHLF1 promoter. In probe
HLp-mZRE, these two ZRE sites were both mutated to
50-TGGTATA. Probe MLp-R had an RRE sequence that
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RRE sequence was mutated, as described elsewhere (12).
A cell lysate prepared from P3HR1 cells that had been
treated with sodium butyrate and TPA was mixed with
0.2mg of a biotinylated probe in a binding buﬀer that
contained 60mM KCl, 12mM HEPES, pH 7.9, 4mM
Tris–HCl, 5% glycerol, 0.5mM EDTA, 1mM dithio-
threitol and 10mg/ml each of leupeptin, aprotinin, and
4-(2-aminoethyl)-benzenesulfonyl ﬂuoride. After it had
been incubated on ice for 45min, the reaction mixture
was mixed with 30ml Streptavidin MagneSphere
Paramagnetic particles (Promega), which had been pre-
equilibrated in the binding buﬀer for 1h at 4 C. The
beads were then washed ﬁve times in the binding buﬀer.
The proteins on the beads were then extracted using 2X
electrophoresis sample buﬀer and boiled for 5min.
Finally, they were separated by sodium dodecyl sulfate
(SDS)-polyacrylamide gel electrophoresis and detected
by immunoblotting (25).
Immunoprecipitation
P3HR1 cells (1 10
7) were treated with TPA and sodium
butyrate for 24h. A lysate was prepared from the cell
using radioimmune precipitation assay (RIPA) buﬀer
(25), followed by three times of sonication under the con-
ditions of 10-s pulses with 10-s cooling at 20% power
using a sonicator (Vibra Cell, Sonics) equipped with a
microprobe. The lysate was centrifuged at 13800g for
5min and the supernatant was mixed with anti-Rta
(1:3000 dilution) (Argene), anti-Zta (1:1000) (Argene) or
anti-MCAF1 (1:1000) (Bethyl) antibody at 4 C for 1h.
Protein-A/G agarose beads (30ml) (Oncogene) were
added to the lysate and the mixture was incubated with
shaking for 1h at 4 C. The beads were collected by cen-
trifugation and washed three times in RIPA buﬀer.
Proteins binding to the beads were eluted by adding
20ml of 2X electrophoresis sample buﬀer and analyzed
by immunoblotting with anti-Rta, anti-Zta, anti-MCAF1
or anti-GFP (Santa Cruze) antibody.
Glutathione S-transferase-pull-down assay
GST, GST-Zta, GST-Rta, GST-MCAF1-C1 or GST-
MCAF1-C2 at a concentration of 40ng/ml in 500ml
NETN buﬀer [20mM Tris–HCl, pH 8.0, 100mM NaCl,
1mM EDTA, 0.5% NP-40 and 10mg/ml each of
leupeptin, aprotinin and 4-(2-aminoethyl)-benzenesulfonyl
ﬂuoride] was added to 30ml glutathione-Sepharose 4B
beads (Amersham Pharmacia Biotech). The mixture was
incubated with shaking for 1h at 4 C. The beads were
washed three times in NETN buﬀer and added to the
Escherichia coli BL21(DE3)(pET-MCAF1-C1), E. coli
BL21(DE3)(pET-Zta) or E. coli BL21(DE3)(pET-Rta)
lysate. The reaction mixture was incubated on ice for
1h. The beads were then washed in NETN buﬀer.
Table 1. Reporter plasmids used in this study
Plasmid Range in promoter
a cis elements in promoter
b
pBMRF1  172 to +20
pBMRF1-mRRE  172 to +20
pBMRF1-mZRE  172 to +20
pEAD  332 to +20
pBHLF1  143 to +16
pBMLF1
c  523 to +38
pZRE  31 to  37 in BRLF1
pRRE  374 to  391 in BMLF1
aThe DNA fragment was inserted into a luciferase reporter vector, pGL2-Basic.
bCrossed rectangle represents mutated sequence; arrow, transcription start site.
cAlthough the BMLF1 promoter contains a sequence resembling that of ZRE, the promoter is not activated by
Zta (30).
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added to the mixture and proteins were extracted from the
beads by heating at 95 C for 5min. Proteins were then
separated by SDS-polyacrylamide gel electrophoresis (27).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (CHIP) assay was per-
formed using a method described elsewhere (28). P3HR1
cells (1 10
7) were treated with TPA and sodium butyrate
to induce the expression of Rta and Zta. DNA–protein
complex that was cross-linked by formaldehyde was
immunoprecipitated with anti-Rta, anti-Zta or anti-
MCAF1 antibodies after the DNA had been fragmented
by sonication. The presence of speciﬁc DNA fragments in
the precipitates was detected by qPCR. Primers used for
amplifying the BHLF1 promoter were 50-TCGCCTTCTT
TTATCCTCTTTTTG and 50-CCCAACGGGCTAAAA
TGACA; BHRF1, 50-CGCGTGCCTTACTGACTT
GTC and 50-CCAGGAAGTGGCGAGCAT; BMRF1,
50-GCCCGCTCACCTACATGAC and 50-GCAGCAGC
AGAAGCCAAC; BMLF1, 50-CCAGATGTCCCTCTA
TCA and 50-AACCTCTTACATCACTCAC. Quantita-
tive PCR was performed on the products of CHIP in trip-
licate by the SYBR Green method using the Power SYBR
Green PCR Master Mix and StepOne Real-Time PCR
system (Applied Biosystems). Standard curves were
generated using serial dilutions of input DNA (100, 10,
1 and 0.1%). The Ct of each reaction was quantiﬁed
against the standard curve.
Immunoﬂuorescence analysis
P3HR1 cells were transfected with pEGFP-Rta. After they
had been cultured for 24h, the cells were harvested by
centrifugation, plated on poly-L-Lysine (Sigma)-coated
coverslips, and ﬁxed with 4% paraformaldehyde in
phosphate-buﬀered saline (PBS) for 30min. Immun-
ostaining was performed using anti-Zta monoclonal
antibody and rabbit anti-MCAF1 polyclonal antibody
and then the cells were treated with ﬂuorescein isothio-
cyanate (FITC)-conjugated donkey anti-mouse IgG poly-
clonal antibody (KPL), or rhodamine-conjugated donkey
anti-rabbit IgG polyclonal antibody (DAKO), using a
method described elsewhere (27). Nuclei were visualized
by staining with 5mg/ml 40-6-diamidino-2-phenylindole
(DAPI). After staining, the cells were observed under an
Olympus confocal laser-scanning microscope (Model
Fluoview 500).
Transient transfection assay
P3HR1 and 293T cells (5 10
6) were transfected with 5mg
of plasmids at 240V, 975mF by electroporation using
a BTX ECM630 electroporator (BTX Instrument).
To suppress MCAF1 expression, 293T cells (1 10
4)
were transfected with 0.3mg pBHLF1, pEAD and
50pmol siRNA MCAF1 or control siRNA (Invitrogen
primer number 130189C06) with Lipofectamin 2000
(Invitrogen). Luciferase assay was performed using a
luminometer (Orion II; Berthod) as described elsewhere
(29). Each transfection experiment was performed at
least three times, and each sample in the experiment was
prepared in duplicate.
RESULTS
Binding of Zta, MCAF1 and Rta to a ZRE in lytic
promoters
This work used four diﬀerent biotinylated probes, Rp-SZ,
Rp-mS, Rp-mZ and Rp-mSZ (Figure 1A), to study the
binding of MCAF1, Rta, Sp1 and Zta to an Sp1 site
and a ZRE in the BRLF1 promoter. A lysate was
prepared from P3HR1 cells that were treated with 12-O-
tetradecanoylphorbol-13-acetate (TPA) and sodium
butyrate to induce the EBV lytic cycle and the expression
of Rta and Zta. Immunoblotting revealed that Sp1,
MCAF1, Rta and Zta were present in the cell lysate
(Figure 1B, lanes 1 and 4). Our earlier study found that
Rta, MCAF1 and Sp1 form a complex on Sp1 sites (12).
Therefore, as expected, this study found the binding of
Rta and MCAF1 to probes Rp-SZ and Rp-mZ (Figure
1B, lanes 2 and 6) because both probes contained an Sp1
site (Figure 1A). Meanwhile, Zta bound to Rp-SZ but not
Rp-mZ (Figure 1B, lanes 2 and 6) because in Rp-mZ, the
ZRE was mutated (Figure 1A). This study also analyzed
the binding of these proteins to Rp-mS, which contained a
mutated Sp1 site (Figure 1A). Although Sp1 did not bind
to the probe, immunoblot analysis revealed the binding of
MCAF1, Rta and Zta (Figure 1B, lane 3). Additionally,
these three proteins did not bind to the probe after the Sp1
site and ZRE were both mutated (Rp-mSZ) (Figure 1A
and B, lane 7), suggesting that Rta and MCAF1 interact
with not only the Sp1 on the Sp1 site but also the Zta on
ZRE. This study also investigated the binding of Rta,
MCAF1 and Zta in the BMRF1 promoter. The region
between  174 and  36 in the BMRF1 promoter, MRp-
RZ, contained one RRE and three ZREs (Figure 1C).
Immunoblot analysis revealed the binding of Rta,
MCAF1 and Zta to a biotinylated MRp-RZ (Figure 1D,
lane 2). These results further indicated that mutating the
RRE in the probe, MRp-mR (Figure 1C), did not aﬀect
the binding of these three proteins (Figure 1D, lane 3).
However, MCAF1 and Zta did not bind to the mutant
probe, MRp-mZ (Figure 1D, lane 4), in which the three
ZREs were mutated (Figure 1C); although the binding of
Rta to the mutant probe was detected (Figure 1D, lane 4).
Following mutation of the RRE and ZREs in the probe
(MRp-mRZ) (Figure 1C), Rta, MCAF1 and Zta no
longer bound to the probe (Figure 1D, lane 5). These
results suggested that Rta, MCAF1 and Zta formed a
complex on ZRE. This study used another ZRE probe,
HLp-Z, which contained the region from  74 to  41 in
the BHLF1 promoter, and showed the binding of these
three proteins to the probe (Figure 1E, lane 2). However,
these proteins did not bind to the probe after the ZRE was
mutated (HLp-mZ) (Figure 1E, lane 3), verifying the
binding of Rta, MCAF1 and Zta to ZRE. When
another probe, MLp-R, which contained an RRE from
the BMLF1 promoter, was utilized, only the binding of
Rta was detected (Figure 1E, lane 5). Furthermore, Rta
did not bind to the probe after the RRE was mutated
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not interact with the Rta that binds to an RRE.
Furthermore, the BMLF1 promoter is known to contain
a sequence resembling that of ZRE (Table 1). However,
Zta does not appear to activate the promoter (30). Our
result showed that Zta did not bind to the MLp-mR
probe, suggesting that the lack of activation is likely
attributed to the inability of Zta to bind to this ZRE-
like sequence (Figure 1E, lane 6).
Co-immunoprecipitation of Zta, MCAF1 and Rta
Our earlier study demonstrated that Rta and MCAF1
interact and the Rta–MCAF1 complex can be co-
immunoprecipitated from a lysate (12). This study con-
ducted a similar study to investigate the interaction
between Zta and MCAF1. Immunoblot analysis revealed
that MCAF1 in the P3HR1 lysate (Figure 2A, lane 1)
was immunoprecipitated by anti-MCAF1 antibody
Figure 1. Binding of Zta, MCAF1 and Rta to ZRE. (A) Probe Rp-SZ contains the sequence from  64 to  28 in the BRLF1 promoter. It also
includes an Sp1 site (oval) and ZRE (rectangle). Probes Rp-mS, Rp-mZ and Rp-mSZ have the same sequence as Rp-SZ, except that the Sp1 site and
ZRE in Rp-SZ were mutated as indicated by a crossed rectangle and a crossed oval. The number represents the nucleotide position relative to the
transcriptional start site, ‘+1’ (arrow). ‘TATA’ represents TATA box. (C) A probe, MRP-RZ, contained the region between  174 and  36 in the
BMRF1 promoter. Probes MRP-mR, MRP-mZ and MRP-mRZ contained a mutated RRE, ZREs and both RRE and ZREs as indicated by crossed
rectangles. (E) Probe HLp-Z contained a ZRE from the BHLF1 promoter. In HLp-Z, the ZRE was mutated. (B, D, E) The probes were added to a
lysate from P3HR1 cells that had been treated with TPA and sodium butyrate. Proteins that were bound to the probes were captured using
streptavidin magnetic beads and analyzed by immunoblotting with anti-MCAF1, anti-Rta, anti-Sp1 and anti-Zta antibodies.
Nucleic Acids Research, 2010,Vol.38, No. 14 4691(Figure 2A, lane 4) and co-immunoprecipitated by anti-
Zta antibody (Figure 2A, lane 3). A parallel experiment
found that Zta in the lysate (Figure 2A, lane 5) was
immunoprecipitated by anti-Zta antibody (Figure 2A,
lane 8) and co-immunoprecipitated with MCAF1 by
anti-MCAF1 antibody (Figure 2A, lane 7). On the other
hand, Zta and MCAF1 were not immunoprecipitated by
anti-IgG antibody (Figure 2A, lanes 2 and 6). These
results showed Zta and MCAF1 interact in vivo.A
similar study revealed that Rta in the lysate (Figure 2B,
lane 1) was immunoprecipitated by anti-Rta antibody
(Figure 2B, lane 3) and co-immunoprecipitated by anti-
Zta antibody (Figure 2B, lane 4). Zta in the cell lysate
(Figure 2B, lane 5) was immunoprecipitated by anti-Zta
antibody (Figure 2B, lane 8) and co-immunoprecipitated
with Rta by anti-Rta antibody (Figure 2B, lane 7). In
negative controls, neither Rta nor Zta was immunopre-
cipitated by anti-IgG antibody (Figure 2B, lanes 2 and 6).
Binding of Zta–MCAF1–Rta complex to ZRE in vivo
P3HR1 cells were treated with TPA and sodium butyrate
to induce the expression of Rta and Zta. After cross-
linked protein–DNA complex was immunoprecipitated
with anti-Zta, anti-MCAF1 and anti-Rta antibodies,
PCR with primers that were complimentary to the se-
quences that ﬂanked the ZRE region in the BHLF1
promoter revealed that DNA fragments that contained
the BHLF1 promoter were immunoprecipitated by these
three antibodies. The amount of promoter captured by
anti-Zta, anti-MCAF1 and anti-Rta antibody exceeded
that from the reaction without adding an antibody, the
negative control (Figure 3A). Adding the anti-IgG
antibody immunoprecipitated the promoter DNA at a
level comparable to that of the negative control (Figure
3A). Similar results were also found for the BHRF1 and
BMRF1 promoters (Figure 3B and C). However, qPCR
revealed that amount of BMLF1 promoter DNA
immunoprecipitated by anti-Rta antibody was signiﬁcant-
ly higher than that immunoprecipitated by anti-Zta and
anti-MCAF1 antibodies (Figure 3D). Zta and MCAF1
did not appear to bind to the ZRE in the promoter.
Subcellular localization of Rta, MCAF1 and Zta
Our earlier study demonstrated the colocalization between
Rta and MCAF1 by confocal microscopy (12). The same
analysis was performed to study the localization of Zta,
MCAF1 and Rta. After pEGFP-Rta was transfected into
TPA-sodium butyrate-treated P3HR1 cells, GFP-Rta was
observed in both the nucleus and the cytoplasm (Figure
4B); Zta was present only in the nucleus (Figure 4C). The
merged image revealed that GFP-Rta and Zta colocalized
in the nucleus (Figure 4D). GFP expressed from pEGFP
was distributed in both the nucleus and the cytoplasm
(Figure 4F) and no colocalization between Zta and GFP
Figure 2. Interaction among Zta, MCAF1 and Rta in vivo.( A) P3HR1 cells were treated with TPA and sodium butyrate. Proteins in the lysate (lanes
1 and 5) were immunoprecipitated (IP) with anti-IgG (lanes 2 and 6), anti-MCAF1 (lanes 4 and 7) and anti-Zta (lanes 3 and 8) antibodies.
Immunoprecipitated proteins were analyzed by immunoblotting (IB) with anti-MCAF1 (lanes 1–4) and anti-Zta (lanes 5–8) antibodies. (B)
Proteins in the lysate (lanes 1 and 5) were immunoprecipitated with anti-IgG (lanes 2 and 6), anti-Rta (lanes 3 and 7) and anti-Zta (lanes 4 and
8) antibodies. Immunoprecipitated proteins were detected by immunoblotting with anti-Rta (lanes 1–4) and anti-Zta (lanes 5–8) antibodies. Lane 1 in
(A) and (B) was loaded with 1% of the cell lysate. Lane 5 in (A) and (B) was loaded with 3% of the cell lysate.
Figure 3. Quantitation of the binding of Zta, MCAF1, and Rta to the
ZREs in the promoters of BHLF1 (A), BHRF1 (B), BMRF1 (C) and
BMLF1 (D). P3HR1 cells were treated with TPA and sodium butyrate.
The binding of Zta, MCAF1 and Rta to the ZREs was investigated by
CHIP analysis using anti-Zta, anti-MCAF1 and anti-Rta antibodies
and by qPCR. The reaction was performed with and without the
addition of anti-IgG antibody as negative controls. The error bar rep-
resents standard error.
4692 Nucleic Acids Research, 2010,Vol.38, No. 14was observed (Figure 4H). Meanwhile, after TPA and
sodium butyrate treatment, Zta that was expressed from
the EBV genome was found to colocalize with MCAF1
in the nucleus (Figure 4J–L). Colocalization was
not observed when cells were untreated with TPA and
sodium butyrate (Figure 4N–P).
Mapping interaction domains in Zta and MCAF1
A co-immunoprecipitation experiment was performed to
delineate the regions in Zta that interact with MCAF1.
293T cells were cotransfected with plasmids that expressed
GFP-ZN, GFP-ZM and GFP-ZC (Figure 5A). Immuno-
blotting using anti-GFP antibody revealed the presence of
GFP-ZN (Figure 5B, lane 1), GFP-ZM (Figure 5B, lane 2)
and GFP-ZC (Figure 5B, lane 3) in the lysate, and the
co-immunoprecipitation of GFP-ZN (Figure 5B, lane 4),
GFP-ZC (Figure 5B, lane 6) but not GFP-ZM (Figure 5B,
lane 5) with MCAF1 by anti-MCAF1 antibody
(Figure 5B, lanes 4–6), indicating that MCAF1 interacts
with the transactivation domain and the region that
contains the DNA-binding and dimerization domains in
Zta (Figure 5A). Exactly how MCAF1 fragments interact
with Zta was also investigated. To do so, plasmids that
expressed truncated GFP-MCAF1 fusion proteins
(Figure 5C) were transfected into P3HR1 cells that had
been treated with TPA and sodium butyrate. After trans-
fection, these proteins were expressed and present in the
cell lysate (Figure 5D, lanes 1–4). Immunoblot analysis
indicated that GFP-fusion proteins that contain the
regions from amino acid 562 to 816 and 1154 to 1270 in
MCAF1 (GFP-MCAF1-DM1 and GFP-MCAF1-DM2)
were co-immunoprecipitated with Zta by anti-Zta
antibody (Figure 5D, lanes 6 and 8). However, GFP
fusion proteins that contained the regions from amino
acid 1 to 561 (GFP-MCAF1-N) (Figure 5D, lane 5) and
from 817 to 1153 (GFP-MCAF1-M) (Figure 5D, lane 7) in
MCAF1 were not co-immunoprecipitated, indicating
that Zta interacts with domains 1 and 2 in MCAF1
that also interact with Sp1, MBD1, and TFIIE (23,24).
Additionally, in GST-pull-down assay, both GST-
MCAF1-C1- and GST-MCAF1-C2-glutathione-
Sepharose beads (Figure 5C) were found to pull down
His-Zta from an E. coli lysate (Figure 5E, lanes 4
and 5). However, GST- or GST-Rta-glutathione-
Sepharose beads did not pull down His-Zta (Figure 5E,
lanes 2 and 3). GST-Zta-glutathione-Sepharose beads also
Figure 4. Subcellular localization of MCAF1, Rta and Zta. P3HR1 cells were transfected with pEGFP-Rta (A–D) or an empty vector, pEGFP
(E–H), and treated with TPA and sodium butyrate (SB). Cells were also treated (I–L) or untreated (M–P) with TPA and sodium butyrate without
transfection. Cells were incubated with monoclonal anti-Zta antibody (C, G, K and O) and rabbit anti-MCAF1 polyclonal antibody (J and N).
DAPI staining revealed the nucleus (A, E, I, M). Cells were observed under a confocal laser-scanning microscope. D, H, L and P are merged images.
Nucleic Acids Research, 2010,Vol.38, No. 14 4693Figure 5. Mapping the interaction domains in MCAF1 and Zta. (A) Various regions in Zta were fused with GFP. Numbers represent the positions
of amino acid in Zta. TA, transactivation domain; DBD, DNA-binding domain; DIM, dimerization domain. (B) Plasmids that expressed GFP-ZN
(lanes 1 and 4), GFP-ZM (lanes 2 and 5) and GFP-ZC (lanes 3 and 6) were transfected into 293T cells. Proteins in the lysates were analyzed by
immunoblotting (IB) with anti-GFP antibody (lanes 1–3). Proteins in the lysate were immunoprecipitated with anti-MCAF1 antibody and examined
by IB with anti-GFP antibody (lanes 4–6). (C) Plasmids that expressed a segment of MCAF1 that was fused with GFP were used to identify the
region in MCAF1 that interacted with Zta. Numbers represent positions of amino acids in MCAF1. Domains 1 and 2 were delineated by Fujita et al.
(23). (D) The plasmids were transfected into P3HR1 cells that were treated with TPA and sodium butyrate. Proteins in the cell lysate that contained
GFP-MCAF1-N (lane 1), GFP-MCAF1-DM1 (lane 2), GFP-MCAF1-M (lane 3) and GFP-MCAF1-DM2 (lane 4) were detected by IB with
anti-GFP antibody (lanes 1–4). Proteins in the lysate were immunoprecipitated with anti-Zta antibody and analyzed by immunoblotting with
anti-GFP antibody (lanes 5–8). (E) The lysate from E. coli BL21(DE3)(pET-Zta) was mixed with GST-Rta-, GST-MCAF1-C1-,
GST-MCAF1-C2- or GST-glutathione-Sepharose-beads. Proteins that were bound to beads were detected by immunoblotting using anti-Zta
antibody (lanes 1–5). E. coli lysates that contained His-Rta, His-MCAF1-C1 and His were mixed with GST-Zta-glutathione-Sepharose beads.
Proteins that were pulled down by the beads were examined by IB with anti-Rta antibody (lanes 6–8). Lanes 1 and 6 were loaded with 0.5% of
the lysate. Lane 9 shows the immunoblot of His-MCAF1-C1 that was puriﬁed by Ni-NTA agarose beads.
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5E, lane 7), suggesting that Rta and Zta do not interact.
Our earlier work demonstrated that Rta interacts with
domain 1 in MCAF1, which also interacts with Zta
(Figure 5D, lane 6), therefore, a bacterial lysate containing
His-MCAF1-C1 was added to the lysate mixture that con-
tained GST-Zta and His-Rta. Immunoblotting revealed
that adding His-MCAF1-C1 enabled GST-Zta-
glutathione-Sepharose beads to pull down His-Rta
(Figure 5E, lane 8), indicating that the interaction
between Rta and Zta involves domain 1 in MCAF1.
ZRE and synergistic activation by Rta and Zta
A reporter plasmid, pBMRF1, which contains a ﬁreﬂy
luciferase gene transcribed from the BMRF1 promoter
was adopted to elucidate how Rta and Zta synergistically
activate transcription. The BMRF1 promoter in this
reporter plasmid contained an RRE and three ZREs
(Figure 6A). In a negative control, this study found that
in 293T cells, transfecting an empty vector, pCMV-3, did
not activate the BMRF1 promoter in pBMRF1; the
luciferase activity exhibited by the reporter plasmid was
at a background level (Figure 6B). However, the luciferase
activity exhibited by the reporter plasmid increased 58-
fold when the cells were cotransfected with pCMV-R
(Figure 6B), indicating that Rta activates the BMRF1
promoter. A similar experiment demonstrated that trans-
fecting pCMV-Z increased the luciferase activity exhibited
by the reporter plasmid 30-fold (Figure 6B), indicating
that Zta also activate the BMRF1 promoter.
Additionally, the luciferase activity was 784-fold higher
than that of the negative control after cotransfecting
with pCMV-R and pCMV-Z (Figure 6B), indicating that
Rta and Zta synergistically activate the BMRF1
promoter. A similar study was performed with
pBMRF1-mRRE (Figure 6A). In this reporter plasmid,
the RRE in the BMRF1 promoter in pBMRF1 was
mutated (Figure 6A). After cotransfecting with this
reporter plasmid and pCMV-R into 293T cells, the
luciferase activity exhibited by the reporter plasmid was
28-fold higher than that exhibited by the negative control
(Figure 6B). Meanwhile, luciferase activity increased
21-fold after the cells were cotransfected with pCMV-Z
(Figure 6B). The 28-fold activation by Rta of the
mutant promoter is unsurprising since Rta often
nonspeciﬁcally activates transcription from an empty
vector (18). Despite the RRE mutation, cotransfecting
293T cells with pCMV-R and pCMV-Z synergistically
increased the activity of the promoter by a factor of 400
(Figure 6B). Moreover, the three ZREs in the promoter
were mutated (pBMRF1-mZRE) (Figure 6A). Although
pCMV-Z did not activate the mutant promoter, transfect-
ing pCMV-R increased the promoter activity 45-fold in
293T cells (Figure 6B), a level resembling that achieved
using pBMRF1. On the other hand, cotransfecting
pCMV-R and pCMV-Z into the cells increased the
luciferase activity of the reporter plasmid by only 19-
fold; less than that achieved using pCMV-R (Figure 6B).
The drop in Rta-activated promoter activity from 45-
fold to 19-fold associated with transfecting pCMV-Z
(Figure 6B) is consistent with the ﬁnding of Giot and
Quinlivan et al. (4,5), which showed that Zta unbound
to ZRE inhibits transcription activation of the BMRF1
promoter by Rta. The DNA-binding domain in Rta is
located in the N-terminal region of a protein from
amino acid 1 to 320 (31). Our earlier study demonstrated
that an Rta mutant containing a mutation with a K213A
mutation in this region does not bind to RRE (12). This
study further demonstrated that the synergy is independ-
ent of the binding of Rta to RRE by conducting similar
reporter analysis of the BMRF1 promoter in 293T cells
with a plasmid, pCMV-R(K213A), that expressed
Rta(K213A). Luciferase assay revealed that pCMV-
R(K213A) alone activated the BMRF1 promoter 3-fold
(Figure 6C). However, Flag-Zta expressed from pTag2-
Zta, activated the promoter 194-fold (Figure 6C).
Additionally, cotransfecting pCMV-R(K213A) and
pTag2-Zta synergistically activated the promoter 685-
fold (Figure 6C). Moreover, two reporter plasmids,
pRRE and pZRE, which contain an RRE and a ZRE
from the BMLF1 and BRLF1 promoters, respectively,
were also used. Cotransfecting 293T cells with pRRE
and pCMV-R increased the activity of the promoter by
a factor of 11 (Figure 6D); cotransfecting pCMV-Z did
not increase the activity of the RRE promoter (Figure
6C). The activity of the RRE promoter increased 12-fold
after cotransfecting pCMV-R and pCMV-Z (Figure 6D)
into the cells, revealing that Rta and Zta do not activate
the RRE promoter synergistically. However, although
pCMV-R and pCMV-Z increased the promoter activity
of pZRE 4.6-fold and 13-fold, respectively, after both
plasmids were cotransfected, the activity of the ZRE
promoter increased by 107-fold, indicating that Rta and
Zta synergistically increase the activity of the ZRE
promoter. Furthermore, immunoblot analysis revealed
that after cotransfecting pCMV-R and pCMV-Z,
pCMV-R did not aﬀect the expression of Zta from
pCMV-Z and vice versa (Figure 6E), suggesting that the
synergistic activation observed is not attributable to an
elevated Rta or Zta expression after cotransfection.
Involvement of MCAF1 in synergistic activation of
EBV lytic promoters by Rta and Zta
Two reporter plasmids, pBHLF1 and pEAD, were
employed herein to study how MCAF1 aﬀects synergistic
activation. In the case of pBHLF1, pCMV-R increased
the activity of the promoter 4.7-fold; pCMV-Z increased
its activity 94-fold; pCMV-R and pCMV-Z, when
cotransfected, increased its activity 524-fold (Figure 7A)
in 293T cells. Meanwhile, pCMV-R increased the activity
of the BMRF1 promoter in pEAD 83-fold, pCMV-Z
increased it 113-fold and pCMV-R and pCMV-Z
increased it 558-fold (Figure 7A) in 293T cells. These
results indicated that Rta and Zta synergistically activate
both the BHLF1 and BMRF1 promoters. Additionally,
transfecting the cells with pcDNA-MCAF1 increased
Zta-activated BHLF1 transcription from 41.6-fold to
73.7-fold (Figure 7A), indicating that MCAF1, although
does not collaborate with Zta to activate transcription
synergistically, promotes the transcription that is activated
Nucleic Acids Research, 2010,Vol.38, No. 14 4695by Zta. Meanwhile, cotransfecting the cells with pcDNA-
MCAF1 increased the transcriptional activity of the
BHLF1 and the BMRF1 promoters that is synergistic-
ally activated by Rta and Zta in a dose-dependent
manner. When cells were transfected with 0.5mgo f
pcDNA-MCAF1, the promoter activity increased 2.8-
fold and 3.8-fold, respectively (Figure 7B). A similar phe-
nomenon was also found in a B lymphocyte cell line,
BJAB. Overexpressing Rta and Zta in the cells activated
the BMRF1 promoter in pEAD 35- and 15-fold,
Figure 6. ZRE and synergistic activation by Rta and Zta. (A) A reporter plasmid, pBMRF1, contains a luciferase gene that is transcribed from the
 172 to+20 region in BMRF1. In this region, the BMRF1 promoter contains an RRE and three ZREs. In pBMRF1-mRRE and pBMRF1-mZRE,
the RRE and ZREs, respectively, are mutated. RRE and ZRE are represented as empty boxes. Mutant sequences are shown as crossed rectangles.
(B) 293T cells were cotransfected with the reporter plasmids, pCMV-R and pCMV-Z. Cells that were transfected with pCMV-3 were used as a
control. (C) 293T cells were also cotransfected with pBMRF1 and pCMV-R(K213A), pTag2-Zta or pCMV-3. (D) Plasmid pRRE contained an RRE
from the BMLF1 promoter and pZRE contained a ZRE from the BRLF1 promoter. 293T cells were cotransfected with the reporter plasmids,
pCMV-R, pCMV-Z and pCMV-3. The luciferase activity of the cells was determined at 24h after transfection. Each transfection experiment was
performed three times, and each sample in the experiment was prepared in duplicate. (E) 293T cells were transfected with pCMV-3, pCMV-R,
pCMV-Z or cotransfected with pCMV-R and pCMV-Z. Rta, Zta and a-tubulin expressed by the cells were examined by immunoblotting.
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synergistically activated the promoter 667-fold (Figure
7C). Expressing MCAF1 by transfection also enhances
the synergistic activation in a dose-dependent manner.
In a cotransfection experiment, the synergistic activation
was further enhanced 2.6-, 3.0- and 4.1-fold when 0.1, 0.3
and 0.5mg of pcDNA-MCAF1 was also transfected
(Figure 7C). Additionally, transfecting MCAF1 siRNA
into 293T cells markedly reduced the intracellular level
of MCAF1 (Figure 8A) and decreased the transcriptional
activity of the BHLF1 and BMRF1 promoters that is syn-
ergistically activated by Rta and Zta 67% and 74%, re-
spectively (Figure 8B). However, MCAF1 siRNA did not
aﬀect the activity of the BMLF1 promoter (Figure 8B).
DISCUSSION
As is generally known, viruses commonly express
abundant amounts of lytic proteins during the productive
cycle. To achieve this, viruses often use viral-encoded tran-
scription factors to promote the transcription of viral
genes. Furthermore, these transcription factors may col-
laborate with each other to activate transcription syner-
gistically to achieve high levels of expression of proteins
that are needed for viral lytic development. For example,
the two human cytomegalovirus (HCMV) immediate-
early proteins, IE1 and IE2, synergistically activate the
HCMV lytic genes (32,33). The human immunodeﬁciency
virus (HIV) Tat protein is known to interact with PCAF
to activate transcription synergistically (34). In EBV, Rta
and Zta are expressed at the onset of the lytic cycle. These
two proteins commonly cooperate with each other and
activate transcription synergistically (3,5,9,17,18). Since
the binding between Rta and Zta has not been proven
experimentally, one model proposes that the simultaneous
binding of Rta and Zta to RRE and ZRE, respectively, in
a promoter is a prerequisite for synergistic activation
(5,19). However, the model may not accurately explain
how the transcription is synergistically activated, since
Rta and Zta activate synergistically the BRLF1
promoter, which does not have an RRE (18).
Accordingly, an alternative model suggests that Rta and
Zta form a complex through an unidentiﬁed protein to
activate transcription synergistically (4).
If the synergistic activation by Rta and Zta involves
an intermediary protein, then this protein is likely to
be MCAF1 since Rta and Zta simultaneously interact
with MCAF1. The evidence for this interaction is that
Rta, MCAF1 and Zta bind to ZRE probes in vitro
(Figure 1B, lanes 3 and 7; Figure 1). This interaction
Figure 7. MCAF1 and synCergistic activation of transcription by Rta and Zta. (A) 293T cells were cotransfected with a reporter plasmid, pBHLF1
or pEAD, and an empty vector, pCMV-3 (CMV), plasmids that expressed Rta (R), Zta (Z) and MCAF1 (M). (B) Cells were also cotransfected with
pCMV-R, pCMV-Z and 0–0.5mg of pcDNA-MCAF1. (C) A similar study was conducted in BJAB cells. The luciferase activity of the cells was
determined 48h following transfection. Each transfection experiment was performed three times, and each sample in the experiment was prepared
in duplicate.
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co-immunoprecipitated (Figure 2); bind to the ZREs
in the BHLF1, BHRF1 and BMRF1 promoters, as
demonstrated by CHIP analysis (Figure 3); and colocalize
in the nucleus (Figure 4). The fact that the BHLF1
promoter includes four ZREs in the oriLyt, which are crit-
ically involved in the EBV lytic replication, implies that
Rta may participate in EBV lytic replication by interacting
with MCAF1 and Zta. This study also establishes that the
interaction between Rta and Zta depends on domain 1
region in MCAF1, where MBD1, Sp1, and TFIIE also
bind (23,24), since adding a peptide that contains the
sequence in this region causes the interaction (Figure 5E).
This study demonstrates that synergistic activation of
transcription by Rta and Zta depends on ZRE but not
RRE. In the BMRF1 promoter, the region from  172
to +20 contains an RRE and three ZREs (Figure 6A).
Results of this study show that mutating the RRE
reduces the increase in synergistic activity from 784-fold
to 400-fold (Figure 6B). However, the 400-fold increase
considerably exceeds those achieved using pCMV-R or
pCMV-Z (Figure 6B), indicating that Rta and Zta syner-
gistically activate the mutant promoter in pBMRF1-
mRRE. In fact, a similar phenomenon was also
observed by an earlier study (5). This result suggests
that, rather than participating in synergistic activation,
Rta, when it binds to RRE, acts alone but does not co-
operate with Zta to activate transcription. Furthermore,
mutating the three ZREs in a promoter, such as
pBMRF1-mZRE (Figure 6A), eliminates the increase in
synergistic activity from 784-fold to 19-fold (Figure 6B),
indicating that after ZREs are mutated, pCMV-R and
pCMV-Z no longer activate the promoter synergistically.
Moreover, the synergistic activation of the ZRE promoter
in pZRE but not the RRE promoter in pRRE (Figure 6D)
further supports the fact that the synergistic activation
depends on ZRE but not RRE. Additionally, Giot et al.
(4) indicated that the DNA-binding domain in Zta is
critical to the synergistic activation, supporting the con-
clusion that ZRE participates in synergistic activation.
Earlier studies of synergistic activation have demonstrated
that after ZRE is mutated in the BMRF1 promoter, Zta
no longer binds to the promoter and Zta that is unbound
to the mutant promoter actually inhibits the transcription
that is activated by Rta (4,5). In HCMV, unbound IE1
was also found to inhibit the transcription that is activated
by IE2 (32,33). The inhibition by unbound Zta may
explain why cotransfecting pCMV-R and pCMV-Z acti-
vates the BMRF1 promoter in pBMRF1-mZRE to an
extent that is lower than achieved using pCMV-R
(Figure 6B). Since the interaction of Rta with MCAF1
prevents the binding of Rta to RRE (Figure 1C, lane 5)
(12), after the mutation of ZRE, the unbound Zta may
form a complex with MCAF1 and Rta, reducing the level
of Rta that binds to RRE to activate transcription.
This study demonstrates that MCAF1 participates in
synergistic activation by Rta and Zta. In a transient trans-
fection study, expressing MCAF1 increases the synergistic
activation of the BHLF1 and BMRF1 promoters in a
dose-dependent manner in both 293T and BJAB cells
(Figure 7B and C). As MCAF1 is expressed constitutively
and abundant in cells (Figure 4), this may explain why
overexpressing MCAF1 does not substantially increase
the synergy (Figure 7B and C). Additionally, introducing
MCAF1 siRNA into the cell reduces the increment in syn-
ergistic activity 67% and 74%, respectively (Figure 8B).
This ﬁnding suggests that Rta and Zta cannot synergistic-
ally activate transcription when MCAF1 is insuﬃcient.
The reduction of the activation by MCAF1 siRNA
cannot be attributed to the likelihood that the siRNA
Figure 8. Knockdown of MCAF1 and synergistic activation. (A) 293T cells were transfected with MCAF1 siRNA (lane 2) or control siRNA
(lane 1). The expression of MCAF1 was determined by immunoblotting using anti-MCAF1 antibody at 48h following transfection. The amount
of a-tubulin in the cell was used as a control. (B) 293T cells were cotransfected with pBHLF1, pEAD, or pBMLF1 with pCMV-R, pCMV-Z and
MCAF1 siRNA or control siRNA. The luciferase activity of the cells was determined 48h following transfection. Each transfection experiment was
performed three times, and each sample in the experiment was prepared in duplicate.
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scription of BMLF1 is unaﬀected (Figure 8B). This study
also attempted to demonstrate the inhibition of transcrip-
tion of BMRF1 from the EBV genome by using the same
siRNA approach (Figure S1). However, the inhibition was
less profound than the results from the transfection study.
This observation may be owing to that, in contrast with
the plasmids transfected into the cell, the copy number of
the EBV DNA is relatively low. The amount of MCAF1
remaining in the cell after siRNA knockdown is probably
adequate to sustain the transcription of BMRF1.
This study further demonstrates that MCAF1 enhances
the transcription of BHLF1 that is activated by Zta
from 41.6-fold to 73.7-fold (Figure 7A). Moreover, an
MCAF1 knockdown by siRNA reduces the enhancement
(Figure S2), indicating that MCAF1 promotes Zta-
activated transcription, although not synergistically.
Furthermore, although Rta interacts with Sp1 through
MCAF1 and enhances Sp1-mediated transcription (12),
Rta and Sp1 do not activate synergistically the transcrip-
tion of an Sp1 reporter plasmid (data not shown).
Similarly, our unpublished data also show that Rta inter-
acts with AP-1 and ATF2 via MCAF1. However, the
interaction does not appear to activate transcription syn-
ergistically (data not shown). These ﬁndings indicate that
the interaction between the MCAF1–Rta complex with a
protein binding to a promoter does not always result in
synergistic activation. Additionally, Francis et al. (19)
showed that although an S186A mutation in Zta abolishes
the transactivation ability, the mutant protein remains
capable of binding to ZRE and collaborates with Rta to
activate the transcription of BMRF1 and BRLF1 syner-
gistically. The ﬁnding suggests that the binding of Zta
to ZRE but not the transactivation capability of Zta is
important to the synergistic activation.
Based on our results, we conclude that Rta interacts
with Zta on ZRE through MCAF1. In this protein
complex, Rta and Zta may act together or recruit add-
itional transcription factors to promote synergistic activa-
tion. Synergistic activation of EBV lytic transcription by
Rta and Zta is critical to the eﬃcient expression of viral
lytic proteins in the lytic cycle. This study demonstrates
that formation of a Zta–MCAF1–Rta complex on ZRE is
the underlying mechanism that causes synergistic
activation, which is critical to EBV lytic development.
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